The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2018 | Venetoclax combinations effective in elderly AML
While venetoclax is widely used in chronic lymphocytic leukemia (CLL) to good effect, previous studies have suggested that the drug does not yield such good results in acute myeloid leukemia (AML). In this video, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Marina Konopleva, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, discusses several recent trials (NCT02203773, NCT02287233) that explored the efficacy of venetoclax in combination with hypomethylating agents or low-dose cytarabine in elderly, untreated AML patients. The results were positive, and Prof. Konopleva finishes by suggesting future implications for these data.
